Background. Sentinel node biopsy (SNB) is commonly performed in contemporary melanoma management, however there is a paucity of long-term quality of life (QoL) estimates required for economic evaluation of this treatment. Methods. A single-center, prospective, cross-sectional study of adults with American Joint Committee on Cancer stage I/II/IIIA melanoma of the limbs, trunk, or neck who had undergone wide excision and SNB, but not complete regional node dissection, was undertaken. Limb volume was measured using perometry, with lymphedema defined as a C10% volume increase in the ipsilateral limb compared with the contralateral limb. The Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire measured QoL. Associations between patient and treatment characteristics were assessed using linear regression. Results. Among 694 patients (median time from SNB of 37 months), 14 (2%) had objectively measured lymphedema (i.e. an increase in limb volume of C10%). Of 687 stage I/II patients with complete QoL data, the mean weighted QoL was 0.745 (standard deviation 0.04) on a 0-1 scale (i.e. death to full health). In multivariable analysis, weighted QoL was 0.0004 higher for each year of increasing age (p = 0.001); 0.011 lower for females (p = 0.001), 0.018 lower following post-SNB limb trauma (p = 0.002); 0.252 lower for patients who perceived a large increase in limb size (p = 0.015); and 0.027 lower with self-reported difficulty in walking, running, or climbing stairs (p = 0.043). Conclusions. Our data suggest that very few patients treated at our institution had lymphedema in the long-term following SNB, with weighted QoL strongly associated with perceived rather than actual changes in limb size.
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Sentinel node biopsy (SNB) is now widely used to stage patients with intermediate-thickness and thick primary cutaneous melanomas. The procedure allows clinicians to assess whether a primary tumor has metastasized to regional lymph nodes, thereby improving prognostic estimates and guiding further management. SNB and wide excision are not major surgical procedures, but complications sometimes occur, including seroma, wound infection, nerve damage, and lymphedema. [1] [2] [3] Lymphedema following regional lymph node dissection has been well-studied, 4 but similar attention has not been given to studying lymphedema following SNB or wide excision. Lymphedema and other complications have been shown to reduce patient quality of life (QoL) during the first 3 months following surgery, 5 however longer-term complications of wide excision and SNB have been largely ignored, despite the fact that lymphedema may not appear for 12-18 months; what evidence is available is from retrospective chart review and subjective reporting. 6 Weighted QoL estimates (also known as utilities) are a measure of patient well-being as perceived by patients at a particular point in time. They measure QoL on a 0-1 scale, with 0 representing death and 1 representing full or complete health. Weighted QoL can be multiplied by survival time to calculate quality-adjusted survival 7 and, in turn, provide the basis for the quality-adjusted life-year (QALY) in economic evaluations. [8] [9] [10] A recent report of weighted QoL in melanoma patients included a small sample of American Joint Committee on Cancer (AJCC) stage IB/II patients who had undergone SNB. 5 The mean weighted QoL for patients in the first 2 months following surgery was 0.579, compared with other surgical procedures such as open cholecystectomy (0.770) 11 or total knee arthroplasty (0.642), 12 and was somewhat higher in the subsequent 2 years following surgery (0.802). It was not clear from the study report whether any of the included participants incurred specific complications of surgery or whether the measurements of lymphedema were objective or subjective.
A large prospective study of 694 patients with primary melanomas of the limbs, trunk, head, or neck who had undergone SNB at the Melanoma Institute Australia 13 was undertaken to assess QoL using the Functional Assessment of Cancer Therapy-Breast (FACT-B) 14 instrument. Lymphedema was described using objective measures, including limb perometry, 15 as well as subjective self-reported perceptions of increase in limb size. The aim of the present analysis was to calculate long-term weighted QoL from FACT-B scores and evaluate the association with carefully documented patient and treatment characteristics. The hypothesis was that weighted QoL would be significantly lower in patients with an objective measure of limb lymphedema C10% compared with their 'control' limb, and with a self-perception of a 'large' increase in limb volume.
METHODS
This was a single-center, prospective, cross-sectional study of 694 consecutively treated adults who had undergone SNB between 2005 and 2008. All were AJCC stage I or II.
The FACT-B Version-3 instrument measured QoL at least 6 months after wide excision and SNB procedure. This instrument consists of 43 questions and assesses six domains related to well-being: physical well-being, social and family well-being, the patient's relationship with their doctor, emotional well-being, functional well-being, and additional concerns the patient may have following surgery. This instrument was chosen rather than the FACT-G, of which it is a subset, because it includes an additional domain with questions relevant to surgery (particularly of axillary lymph nodes) and other cancer treatments relevant to patients with melanoma. The FACT-M (melanoma) instrument was developed in 2004 and validated in 2008 16 and therefore was not available at the time of this study. For the current analysis, patients were asked a number of additional questions covering sociodemographics, the type of surgery received, and post-surgical complications (Appendix 1).
Mean FACT-B scores were converted to weighted QoL scores using two published algorithms. The first algorithm, by Cheung and colleagues, 17 transforms FACT scores to weighted QoL using a mapping equation from FACT to the EuroQol EQ-5D, based on a study of 558 cancer patients (see Technical Appendix 2). Weighted QoL scores from the EQ-5D are one of the most widely used in economic evaluations, and, a priori, this was chosen as our reference case because it used all the FACT data. A second algorithm, devised by Dobrez et al., 18 converts FACT scores to weighted QoL scores using four questions from the FACT instrument, based on the time trade-off approach among 1433 cancer patients (Appendix 2).
In the current analysis, once FACT-B scores were converted to weighted QoL, linear regression models were constructed, with weighted QoL as the dependent variable. Separate models were created for the QoL estimate from each algorithm to assess the association of a range of predictor variables. Continuous variables included patient age at assessment, body mass index (BMI; kg/m 2 ), Breslow thickness (mm), number of SNB sites, number of lymph nodes retrieved during SNB, and time from surgery to assessment. Categorical variables included sex, primary site of melanoma (limb, trunk, neck), primary surgical procedure (local excision, wide excision and primary closure, wide excision and grafting, wide excision and flap repair, amputation), SNB site (groin, axilla, neck), the occurrence of surgical complications (including hematoma, infection, seroma, deep vein thrombosis [DVT], numbness), trauma to the limb nearest the site of SNB (including venepuncture, blood pressure measurement, vaccination, cuts or sunburn, insect bites), prolonged car or airplane trips following surgery, adjuvant radiotherapy or immunotherapy, difficulty walking, running, or climbing stairs, and difficulty with daily activities such as showering, cooking, and shopping.
Difference in limb volume (ml) between operated and control limbs was measured on the same day as the QoL survey, using an optoelectronic limb volumeter (perometer [350S; Pero-System Messgeraete GmbH, Wuppertal, Germany]) and water displacement. The difference in limb size was also assessed objectively by limb circumference measurements. The objective measure of lymphedema used in this analysis was C10% volume difference between limbs by perometry. 19 This is a widely used definition applied in clinical studies that implies a clinically meaningful amount of limb swelling. 19 Because health-related QoL is defined as the subjective assessment of the impact of disease and treatment across the physical, psychological, social, and somatic domains of functioning and well-being, 20 it was important that lymphedema also be measured subjectively. Patients answered a yes/no question about whether they noticed a change in limb size after surgery, their perception of the degree of change in limb size (slight, moderate or large), and the length of time (in months) following surgery before a change was noticed.
Statistical Analysis
To explore the association between the variables of interest and weighted QoL, univariate analyses were initially performed for each variable, with the mean score as the dependent variable. Variables with a hypothesized association to weighted QoL, and those with a p value \0.25 on univariate analyses, were included in our multivariable linear regression model, which was then refined through backward stepwise elimination. Model fit was assessed by examination of residuals and each model's adjusted R 2 statistic. 21 The STROBE statement 22 for observational studies was used to guide the reporting of the results of this study. Ethical approval was granted by the Sydney Local Health District Human Ethics Committee (X05-0173) as part of the broader study into lymphedema following SNB for melanoma. 23 
RESULTS
Overall, 694 stage I/II melanoma patients recruited for the lymphedema study participated in the QoL study (median age 60 years, 58% males) ( participants, and lower neck for three participants who had an axillary SNB (0.4%). Overall, 238 (34%) patients had SNB of the groin, 411 (59%) had SNB of the axilla, and 38 (6%) had SNB of the neck. Seventy (18%) participants had SNB at more than one site. The median number of lymph nodes retrieved was two (IQR 1-3).
The median time between SNB and assessment was 37 months (3.05 years, IQR 1.65-5.46). An increase in limb size following surgery was reported by 160 patients (23%). Of these, 96 (14%) reported a slight increase, 47 (7%) reported a moderate increase, and 16 (2%) reported a large increase. Perometer measurements identified 14 patients (2%) with a C10% increase in limb volume ( Table 2 ). For axillary SNB and groin SNB patients, 1% and 2% had perometer measurements increase by C10%, respectively. Patients with a primary melanoma on the limb had a significantly higher mean limb volume (p = 0.0017) than patients with a primary on the trunk, and were more likely to perceive a moderate to large increase in limb size (p = 0.008).
Among 694 patients with stage I/II disease, seven had multiple missing QoL items and were excluded from the main QoL analysis because the EQ-5D could not be calculated. In the remaining 687 patients, 46 were missing a single item in a single QoL subscale which was imputed by taking the mean value of the available scores. Mean weighted QoL for melanoma health states for the 687 patients are presented in Table 3 and Webtable 1. Univariate and multivariable analyses of the weighted QoL are shown in Table 4 . The final multivariable model included age, sex, SNB limb trauma, perceived degree of limb size change, time from surgery to assessment, and difficulty with walking, running, or climbing stairs. Weighted QoL was 0.0004 higher for each year increase in age (p = 0.001), 0.011 lower for females (p = 0.001), 0.018 lower for patients with SNB limb trauma (p = 0.002), 0.252 lower for patients with a large self-perceived increase in limb size (p = 0.043), and 0.027 lower for patients who had difficulty walking, running, or climbing stairs. There was no significant difference in mean weighted QoL for those with an objective (perometrymeasured) increase in limb size, and no significant QoL difference related to SNB site (i.e. groin, axilla, or neck). There was no significant difference in mean weighted QoL among those less than 2 years, compared with those more than 2 years, from the time of surgery.
DISCUSSION
Our data suggest that after a median follow-up time of 3 years, only 2% of patients treated with wide excision and axillary or groin SNB for cutaneous melanoma have objectively measured lymphedema, but a larger proportion (9%) perceived that they had an increase in limb size consistent with lymphedema. A recent systematic review 24 noted a pooled 1.3% incidence of lymphedema following SNB from 21 studies, which is similar to our study; however, many of these studies did not include objective measurements of limb volumes, which makes comparison between studies difficult. Theodore et al. 6 found a 6% rate for axillary SNB and a 10% rate for groin SNB. These figures are consistent with the patient-reported figures in this study, but much higher than the objective measurements.
Factors associated with lower QoL included younger age, female sex, post-SNB limb trauma, a self-perceived large increase in limb size, and difficulty with walking, running, or climbing stairs. Weighted QoL was not significantly associated with the primary melanoma site or SNB site, the number of lymph nodes retrieved, or BMI. The long-term mean weighted QoL for patients treated with wide excision and SNB was 0.745 on a utility scale of 0-1 (death to full health).
Our study found a similar mean weighted QoL as the study by Tromme et al., 4 but a substantially lower weighted QoL relative to other smaller studies of stage I and II melanoma patients. 5, 25, 26 For example, King et al. 26 reported a mean weighted QoL of 0.931 for 80 stage I patients, 0.900 for 11 stage II patients, and 0.908 for 10 stage III patients 2-8 years post-diagnosis. Askew et al. 25 calculated a mean score of 0.91 for 102 stage I/II patients. However, it is not clear in either of these studies whether the patients underwent an SNB or were treated with wide excision only. All our patients underwent SNB in addition to a wide excision, usually via two separate surgical incisions, which may have influenced the weighted QoL in our study. Our findings were consistent with the study of De Vries et al., who also reported no significant difference in QoL for patients undergoing SNB in the groin compared with the axilla. 3 Our finding that females had a lower QoL than males is consistent with a number of previous studies [27] [28] [29] [30] [31] in which women reported significantly higher levels of anxiety than men surrounding the melanoma diagnosis.
We have shown a relationship between QoL and difficulty with functional mobility. In our study, patients who had difficulty walking, running, or climbing stairs had significantly worse QoL (0.03 lower) compared with those without these difficulties. This finding is consistent with a number of previous studies that have shown an association between psychological distress and disturbing limb sensations in patients with postoperative lymphedema. [32] [33] [34] [35] Our study did not show a significant association between QoL and objectively measured limb volume. Instead, the perception by the patient of increased limb size was significantly associated with lower QoL. This concept is supported by evidence from studies of women with breast cancer. In one study of breast cancer treatment-related lymphedema, perceived difference in arm size was correlated with symptom intensity and symptom-induced distress, and greater perceived limb size was associated with increased symptom burden. 36 
Study Limitations
Our study was cross-sectional in design and is therefore limited to a single QoL assessment at one point in time. We do not know if weighted QoL changed from the early postoperative period to the late postoperative period in each patient. We did not collect data on comorbid conditions that may have influenced weighted QoL in some participants, for example depression; this may limit the interpretation of our findings. Additionally, our objective perometry measure of lymphedema, a C10% difference in limb size between the ipsilateral and contralateral limb, while relatively robust for the lower limb, may not account for differences in upper limb size due to right-or lefthandedness as there were no pretreatment measurements.
The FACT-M, 16 an assessment tool designed specifically for patients with melanoma, was not available at the time of this study; however, this is not likely to have changed the weighted QoL results for this study as each algorithm only used the generic components of the FACT-G in their transformation of raw scores. The higher mean QoL weight with the Dobrez algorithm, compared with the Cheung algorithm, is not surprising as Dobrez et al. excluded the contribution of all the Emotional Wellbeing QoL items on the FACT, as well as relevant items from the Physical and Functional domains that might reduce QoL, such as pain, feeling bothered by side effects of treatment, sleep quality, and contentment.
The findings of our study may differ from those of others who used a direct measure of weighted QoL, such as administering the EQ-5D directly, 5 rather than transforming scores from the FACT-B to obtain weighted QoL estimates. However, the strengths of our study include a very large sample size and detailed, accurate measurements of patient and treatment characteristics that have enabled mean estimates of weighted QoL following SNB to be obtained with a high degree of precision, and a robust analysis of the factors associated with differences in QoL.
Further Research
Our study raises important questions for further research, including the need for longitudinal assessment of weighted QoL suitable for economic evaluation, ideally measured before SNB and at 3, 12, and 36 months postoperatively, as well as among those undergoing wide excision only. In addition, better objective measures of lymphedema, a condition that is difficult to characterize, are needed. This could be undertaken pre-and postsurgery using bioimpedance, a technique that was not widely available or evaluated when our study was conducted. 
CONCLUSIONS
Our data suggest that very few patients undergoing a wide excision and SNB for cutaneous melanoma have objective limb lymphedema in the long term, and this measure is not associated with self-reported QoL. Factors associated with lower QoL include younger age, female sex, post-SNB limb trauma, a perceived large increase in limb size (up to 9% of patients), and difficulty with walking, running, or climbing stairs. Weighted QoL utilities from this large melanoma study can be used in QALY calculations for economic evaluations of new technologies and melanoma surgical procedures.
